Financial Data and Key Metrics Changes - The company reported Q1 2023 net sales of $71.7 million, a nearly 22% increase year-over-year, marking the highest first-quarter performance in five years [51][101] - Gross profit margin improved to 82.7%, with adjusted EBITDA of $5.5 million, a significant turnaround from a loss of $1.7 million a year ago [24][98] - Net loss decreased to $5 million from $10.5 million in the previous year [98] Business Line Data and Key Metrics Changes - The Wound & Surgical segment generated net sales of $70.6 million, reflecting approximately 21% growth, with a contribution margin of 28.5% [69] - The company is focusing on enhancing its product portfolio and expanding geographically, with new products launched contributing to growth [30][55] Market Data and Key Metrics Changes - The company experienced growth across all sites of service, with a notable increase in the private office segment, which had been challenging due to the Medicare reimbursement environment [56] - Initial sales began in Japan, with expectations for adoption to ramp up in the coming months [58] Company Strategy and Development Direction - The company aims to build on its leadership position in the Wound & Surgical markets by enhancing its product offerings and expanding into adjacent markets [55][31] - A focus on expense management and continuous process improvement is emphasized to ensure profitable growth over time [33] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about EBITDA margin improvement as the business scales, driven by the performance of the sales organization [2] - The company anticipates low double-digit topline growth for the foreseeable future, with a cautious approach to expectations due to market dynamics [76][111] Other Important Information - The company is nearing the resolution of legal expenses related to past issues, which is expected to improve capital utilization moving forward [75] - The company has a robust pipeline of new products and continues to invest in innovation to remain competitive [8][132] Q&A Session Summary Question: Topline performance in the quarter - Management noted that approximately 5% of growth was attributed to easier comparisons from the previous year and an extra shipping day [81] Question: Adjusted EBITDA performance - The $5.5 million in adjusted EBITDA was driven by revenue growth and restructuring activities, with expectations for continued improvement in gross margins [87][114] Question: Impact of OIG recommendations - Management acknowledged that the OIG letter may have influenced private practices to avoid certain products, but the full impact is still uncertain [118] Question: New product contributions - New products have been successful and are significant contributors to year-over-year growth, with ongoing investments in research to support this [125][151] Question: Revenue growth in Japan - Initial sales in Japan are expected to grow, with ongoing training for providers to support product adoption [155]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____________________to______________________ Commission File Number 001-35887 MIMEDX GROUP, INC. (Exact name of registrant as specified in its charter) Florida 26-27925 ...

MiMedx Group, Inc. (NASDAQ:MDXG) Q4 2022 Results Conference Call February 28, 2023 5:00 PM ET Company Participants Matt Notarianni - Head, IR Joe Capper - CEO Pete Carlson - CFO Conference Call Participants Anthony Petrone - Mizuho Group Carl Byrnes - Northland Capital Markets Swayampakula Ramakanth - H.C. Wainwright John Vandermosten - Zacks Operator Good afternoon, and thank you for standing by. Welcome to the MiMedx Fourth Quarter and Full Year 2022 Operating and Financial Results Conference Call. At thi ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________to __________ Commission file number 001-35887 MIMEDX GROUP, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation ...

MiMedx Group, Inc. (NASDAQ:MDXG) Q3 2022 Earnings Conference Call November 2, 2022 5:00 PM ET Company Participants Matt Notarianni ??? Head-Investor Relations Todd Newton ??? Interim Chief Executive Officer Pete Carlson ??? Chief Financial Officer Rohit Kashyap ??? President-Wound and Surgical Robert Stein ??? President-Regenerative Medicine Conference Call Participants Anthony Petrone ??? Mizuho Group RK ??? H.C. Wainwright Carl Byrnes ??? Northland Capital John Vandermosten ??? Zacks Operator Good aftern ...

Q3:22 Financial Results 1 November 2, 2022 This presentation includes forward-looking statements. Forward-looking statements are subject to risks and uncertainties, and the Company cautions investors against placing undue reliance on such statements. Actual results may differ materially from those set forth in the forward-looking statements. Such forward-looking statements include statements regarding: • future sales or sales growth; • the effectiveness of amniotic tissue as a therapy for any particular ind ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____________________to______________________ Commission File Number 001-35887 MIMEDX GROUP, INC. (Exact name of registrant as specified in its charter) Florida 26-2 ...

MiMedx Group, Inc. (NASDAQ:MDXG) Q2 2022 Earnings Conference Call August 3, 2022 8:30 AM ET Company Participants Jack Howarth ??? Senior Vice President-Investor Relations Tim Wright ??? Chief Executive Officer Pete Carlson ??? Chief Financial Officer Rohit Kashyap ??? President Wound Care and Surgical Robert Stein ??? President, Regenerative Medicine and Biologics Innovation Conference Call Participants Anthony Petrone ??? Mizuho Group RK ??? H.C. Wainwright Carl Byrnes ??? Northland Capital Markets John Va ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____________________to______________________ Commission File Number 001-35887 MIMEDX GROUP, INC. (Exact name of registrant as specified in its charter) Florida 26-279255 ...

Financial Data and Key Metrics Changes - The company reported net sales of $58.9 million for Q1 2022, a slight decrease of 1.8% from $60 million in Q1 2021, primarily due to the loss of sales from micronized and particulate products in the U.S. [34] - The advanced wound care portfolio, which includes tissue and cord products, grew by $7.2 million or 13% year-over-year [36]. - Gross margin for the quarter was 83.1%, down from 83.9% in the previous year, influenced by inflationary pressures on materials and labor costs [37]. - The net loss for the quarter was $10.5 million compared to a net loss of $8.4 million in the prior year [42]. Business Line Data and Key Metrics Changes - The continuing portfolio of tissue and cord products achieved a 13% year-over-year growth in net sales [8]. - The company faced a 13% shortfall due to Section 351 products coming off the market, but strong performance in the continuing portfolio helped close that gap [35]. Market Data and Key Metrics Changes - The company anticipates a total addressable market in Japan of over 600,000 patients for EPIFIX, with an expected access to approximately 100,000 patients [19]. - The company is preparing for the launch of two new products in the U.S., AMNIOEFFECT and PCM, expected to launch in the second half of 2022 [19][22]. Company Strategy and Development Direction - The company has created two internal business units: one focused on Wound Care and Surgical recovery markets, and the other on regenerative medicine technologies [29][30]. - The company aims to launch two new products each year to improve its product vitality index [29]. - The strategic focus includes expanding into the surgical recovery market and enhancing the regenerative medicine pipeline, particularly for knee osteoarthritis [30][31]. Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving 11% to 14% growth in the continuing portfolio for 2022, despite challenges from new product launches and market entries [43][55]. - The company is focused on addressing the treatment void in knee osteoarthritis and believes its products can significantly impact this market [138]. Other Important Information - The company is working on a micronized dHACM injectable platform, with plans to initiate a clinical trial for knee osteoarthritis later in the year [23][24]. - The company has been assessing third-party collaborators to assist with clinical trial oversight and data management [25]. Q&A Session Summary Question: Why is the company being conservative with full-year guidance despite strong growth? - Management acknowledged the strong Q1 results but noted challenges ahead due to new product launches and market entries, which informed their conservative outlook [55]. Question: Will AMNIOEFFECT and PCM launch simultaneously? - AMNIOEFFECT will have a limited market release starting in June, while PCM is expected to launch in the second half of the year without a limited release [60]. Question: What is the market missing regarding the company's core business and pipeline potential? - Management highlighted the strong fundamentals of the business, including three consecutive quarters of growth, and emphasized the significant market potential for knee osteoarthritis treatments [72][76]. Question: What specific changes will improve the stability of the micronized dHACM products? - The company has reduced the shelf life of the micronized product from five years to two years and made changes in manufacturing to enhance stability [100]. Question: How is inflation impacting the business? - The primary inflationary pressure is seen in labor costs, while raw materials, particularly donated placenta, remain unaffected by inflation [124]. Question: Will the two new products come from separate divisions? - Both AMNIOEFFECT and PCM are developed within the Wound Care and Surgical recovery group, while the regenerative medicine group focuses on clinical and research aspects [117].